Story perspectives

BrainsWay Secures FDA Approval for Faster Depression Treatment

9/18/2025

48 8

Summary

Story summary

BrainsWay Ltd. gained FDA clearance for a six-day accelerated treatment protocol using its Deep TMS system for major depressive disorder (MDD).
This new approach requires fewer visits than the standard four-week treatment.
Clinical trials demonstrated similar outcomes in depression score reductions and remission rates between both protocols.
No severe adverse events were reported, confirming the treatment's safety.
Following the announcement, BrainsWay's stock increased by 11.9%.

1 of 1

Story summary

BrainsWay Ltd. gained FDA clearance for a six-day accelerated treatment protocol using its Deep TMS system for major depressive disorder (MDD).
This new approach requires fewer visits than the standard four-week treatment.
Clinical trials demonstrated similar outcomes in depression score reductions and remission rates between both protocols.
No severe adverse events were reported, confirming the treatment's safety.
Following the announcement, BrainsWay's stock increased by 11.9%.